| Autor: |
Lima H; Faculdade de Medicina, Pontifícia Universidade Católica de Campinas (PUCC), Campinas 13087-571, Brazil., Etchebehere M; Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo 05652-000, Brazil., Bogoni M; Hospital Erasto Gaertner, Curitiba 81520-060, Brazil.; Diagnóstico Avançado por Imagem (DAPI), Curitiba 80430-210, Brazil., Torricelli C; Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil., Nogueira-Lima E; Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil., Deflon VM; São Carlos Institute of Chemistry, University of São Paulo (USP), São Carlos 13566-590, Brazil., Lima M; Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil.; Medicina Nuclear de Campinas (Grupo MND), Campinas 13020-432, Brazil., Etchebehere E; Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil.; Medicina Nuclear de Campinas (Grupo MND), Campinas 13020-432, Brazil. |
| Abstrakt: |
Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases. Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment. For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and/or determine overall survival gain. The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model. |
